Drug Trial Radar · NCT06939504
A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
May 4, 2025
Primary completion
Jun 3, 2025
Study completion Jun 23, 2025
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase Ⅰ study to evaluate the relative bioavailability of HRS-9813 capsule and tablet in healthy subjects and the effect of food on the pharmacokinetics of HRS-9813 capsule.
Conditions
- Pulmonary Fibrosis
Interventions
HRS-9813 CapsuleDrug
HRS-9813 capsule.
HRS-9813 TabletDrug
HRS-9813 tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration of HRS-9813 capsule (Cmax)Time frame: Day 1-Day 23.
- Maximum observed concentration of HRS-9813 tablet (Cmax)Time frame: Day 1-Day 23.
- Area under the concentration-time curve from time 0 to infinity of HRS-9813 tablet (AUC0-inf)Time frame: Day 1-Day 23.
- Area under the concentration-time curve from time 0 to infinity of HRS-9813 capsule (AUC0-inf)Time frame: Day 1-Day 23.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.